The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
Open accessAbstract
CYP2C19 is one of the principal enzymes involved in the bioactivation of the antiplatelet prodrug clopidogrel. A common loss-of-function allele, CYP2C19*2 (c.681G>A; rs4244285), is associated with increased risk for serious adverse cardiovascular events in both heterozygous and homozygous patients (~25–50% of the population) with acute coronary syndromes (ACSs) who are receiving clopidogrel, particularly among those undergoing percutaneous coronary intervention (PCI). We provide evidence from published literature and guidelines for CYPC19 genotype–directed antiplatelet therapy (periodically updated at http://www.pharmgkb.org). Clinical Pharmacology & Therapeutics (2011) 90 2, 328–332. doi:10.1038/clpt.2011.132
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Cited by
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Implementation and utilization of genetic testing in personalized medicine
Scott, S., Abul-Husn, N., Owusu Obeng, A., Sanderson, S., & Gottesman, O. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s48887 · Cited by 106
Self-citationEthnically diverse pluripotent stem cells for drug development
Fakunle, E. S., & Loring, J. F. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.10.007 · Cited by 27
Metadata
- Authors
- Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-06-29
- Volume
- 90
- Issue
- 2
- Pages
- 328-332
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2028938803
- Cited by
- 484
- References
- 2
- FWCI
- 37.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. https://app.cochat.ai/papers/10.1038/clpt.2011.132
- The paper
- Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011). Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy. Clinical Pharmacology & Therapeutics. https://doi.org/10.1038/clpt.2011.132
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
